CO2019005038A2 - Inhibidores de magl - Google Patents
Inhibidores de maglInfo
- Publication number
- CO2019005038A2 CO2019005038A2 CONC2019/0005038A CO2019005038A CO2019005038A2 CO 2019005038 A2 CO2019005038 A2 CO 2019005038A2 CO 2019005038 A CO2019005038 A CO 2019005038A CO 2019005038 A2 CO2019005038 A2 CO 2019005038A2
- Authority
- CO
- Colombia
- Prior art keywords
- magl inhibitors
- compositions
- useful
- magl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423095P | 2016-11-16 | 2016-11-16 | |
| PCT/US2017/061867 WO2018093946A1 (en) | 2016-11-16 | 2017-11-15 | Magl inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019005038A2 true CO2019005038A2 (es) | 2019-05-31 |
Family
ID=62107273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0005038A CO2019005038A2 (es) | 2016-11-16 | 2019-05-16 | Inhibidores de magl |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9981930B1 (enExample) |
| EP (1) | EP3541822B1 (enExample) |
| JP (1) | JP6987859B2 (enExample) |
| KR (1) | KR20190077087A (enExample) |
| CN (1) | CN110248947B (enExample) |
| AR (1) | AR110088A1 (enExample) |
| AU (1) | AU2017361250A1 (enExample) |
| BR (1) | BR112019009991A2 (enExample) |
| CA (1) | CA3043612A1 (enExample) |
| CL (1) | CL2019001335A1 (enExample) |
| CO (1) | CO2019005038A2 (enExample) |
| CR (1) | CR20190243A (enExample) |
| DO (1) | DOP2019000121A (enExample) |
| EA (1) | EA201991074A1 (enExample) |
| EC (1) | ECSP19035377A (enExample) |
| ES (1) | ES2908632T3 (enExample) |
| IL (1) | IL266550A (enExample) |
| JO (1) | JOP20190105A1 (enExample) |
| MA (1) | MA46860A (enExample) |
| MX (1) | MX2019005771A (enExample) |
| NI (1) | NI201900050A (enExample) |
| PE (1) | PE20191146A1 (enExample) |
| PH (1) | PH12019501102A1 (enExample) |
| RU (1) | RU2019116514A (enExample) |
| TN (1) | TN2019000150A1 (enExample) |
| TW (1) | TW201831458A (enExample) |
| WO (1) | WO2018093946A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ627750A (en) | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| US10450302B2 (en) | 2015-05-11 | 2019-10-22 | Lundbeck La Jolla Research Center, Inc. | Methods of treating inflammation or neuropathic pain |
| CN109996790B (zh) | 2016-09-19 | 2023-05-16 | H.隆德贝克有限公司 | 哌嗪氨基甲酸酯及其制备和使用方法 |
| JOP20190107A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CA3043609A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| PL3541807T3 (pl) | 2016-11-16 | 2022-01-17 | H. Lundbeck A/S | Krystaliczna postać inhibitora magl |
| JOP20190106A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| UA126685C2 (uk) | 2017-08-29 | 2023-01-11 | Луннбек Ла-Холья Рісьоч Сенте, Інк. | Сполуки, які є модуляторами magl, і способи їх отримання і застосування |
| EA202091113A1 (ru) * | 2017-11-02 | 2020-08-28 | Айкурис Гмбх Унд Ко. Кг | Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv) |
| MA52635A (fr) | 2018-05-15 | 2021-03-24 | H Lundbeck As | Inhibiteurs de magl |
| WO2021214550A1 (en) * | 2020-04-21 | 2021-10-28 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| TWI904281B (zh) | 2020-11-13 | 2025-11-11 | 丹麥商Ｈ 朗德貝克公司 | Magl抑制劑 |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibiting monoacylglycerol lipase (magl) |
| WO2023213854A1 (en) | 2022-05-04 | 2023-11-09 | H. Lundbeck A/S | Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor. |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (enExample) | 1967-10-17 | 1970-06-01 | ||
| JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
| WO1989011794A1 (fr) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Inhibiteur de la croissance de plantes |
| AU3226993A (en) | 1991-11-27 | 1993-06-28 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
| DE69408873T2 (de) | 1993-12-22 | 1998-07-09 | Shell Int Research | Verfahren zur herstellung von carbamaten |
| WO1997018196A1 (en) | 1995-11-15 | 1997-05-22 | Zeneca Limited | Herbicidal substituted pyrazole compounds |
| AU3440597A (en) | 1996-07-02 | 1998-01-21 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
| US6503713B1 (en) | 1999-10-04 | 2003-01-07 | University Of Medicine And Dentistry Of New Jersey | Methods for identifying RNA binding compounds |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| WO2005063698A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific & Industrial Research | Process for preparing carbamates |
| AU2005214376A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists |
| TW200538127A (en) * | 2004-04-07 | 2005-12-01 | Millennium Pharm Inc | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| CA2589877A1 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| WO2006074025A1 (en) | 2004-12-30 | 2006-07-13 | Janssen Pharmaceutica N.V. | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
| JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| US20100234351A1 (en) | 2006-02-23 | 2010-09-16 | Takeda Pharmaceutical Company Limited | Fused nitrogen-comprising heterocyclic compound |
| CN101679408B (zh) | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| JP2010519337A (ja) | 2007-02-26 | 2010-06-03 | コーサン バイオサイエンシーズ， インコーポレイテッド | カルバメート化合物 |
| JP2008239616A (ja) * | 2007-02-28 | 2008-10-09 | Iyaku Bunshi Sekkei Kenkyusho:Kk | Ｈｄｌ上昇剤 |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| JP2011528368A (ja) | 2008-07-16 | 2011-11-17 | シェーリング コーポレイション | 二環式ヘテロ環誘導体およびｇｐｃｒモジュレーターとしてのその使用 |
| WO2010056309A2 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| WO2010111050A1 (en) | 2009-03-23 | 2010-09-30 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| ES2433235T3 (es) | 2009-11-03 | 2013-12-10 | Bayer Intellectual Property Gmbh | Fluorouretanos como aditivos en una formulación de fotopolímero |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| SMT201800334T1 (it) | 2012-01-06 | 2018-09-13 | Agios Pharmaceuticals Inc | Composti terapeuticamente attivi e loro metodi di utilizzo |
| NZ627750A (en) * | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| EP2828253A1 (en) | 2012-03-19 | 2015-01-28 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| US9828379B2 (en) | 2013-07-03 | 2017-11-28 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2016149401A2 (en) * | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| US10450302B2 (en) * | 2015-05-11 | 2019-10-22 | Lundbeck La Jolla Research Center, Inc. | Methods of treating inflammation or neuropathic pain |
| US10463753B2 (en) * | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| US10781211B2 (en) * | 2016-05-12 | 2020-09-22 | Lundbeck La Jolla Research Center, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190107A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
-
2017
- 2017-06-16 JO JOP/2019/0105A patent/JOP20190105A1/ar unknown
- 2017-11-15 TN TNP/2019/000150A patent/TN2019000150A1/en unknown
- 2017-11-15 AR ARP170103183A patent/AR110088A1/es unknown
- 2017-11-15 ES ES17871883T patent/ES2908632T3/es active Active
- 2017-11-15 CN CN201780083635.4A patent/CN110248947B/zh not_active Expired - Fee Related
- 2017-11-15 KR KR1020197016859A patent/KR20190077087A/ko not_active Withdrawn
- 2017-11-15 MX MX2019005771A patent/MX2019005771A/es unknown
- 2017-11-15 RU RU2019116514A patent/RU2019116514A/ru not_active Application Discontinuation
- 2017-11-15 MA MA046860A patent/MA46860A/fr unknown
- 2017-11-15 CR CR20190243A patent/CR20190243A/es unknown
- 2017-11-15 US US15/814,318 patent/US9981930B1/en not_active Expired - Fee Related
- 2017-11-15 EP EP17871883.9A patent/EP3541822B1/en active Active
- 2017-11-15 JP JP2019523589A patent/JP6987859B2/ja not_active Expired - Fee Related
- 2017-11-15 EA EA201991074A patent/EA201991074A1/ru unknown
- 2017-11-15 PE PE2019001015A patent/PE20191146A1/es unknown
- 2017-11-15 WO PCT/US2017/061867 patent/WO2018093946A1/en not_active Ceased
- 2017-11-15 BR BR112019009991A patent/BR112019009991A2/pt not_active Application Discontinuation
- 2017-11-15 AU AU2017361250A patent/AU2017361250A1/en not_active Abandoned
- 2017-11-15 CA CA3043612A patent/CA3043612A1/en not_active Abandoned
- 2017-11-16 TW TW106139750A patent/TW201831458A/zh unknown
-
2019
- 2019-05-12 IL IL266550A patent/IL266550A/en unknown
- 2019-05-16 CO CONC2019/0005038A patent/CO2019005038A2/es unknown
- 2019-05-16 DO DO2019000121A patent/DOP2019000121A/es unknown
- 2019-05-16 NI NI201900050A patent/NI201900050A/es unknown
- 2019-05-16 CL CL2019001335A patent/CL2019001335A1/es unknown
- 2019-05-16 PH PH12019501102A patent/PH12019501102A1/en unknown
- 2019-05-17 EC ECSENADI201935377A patent/ECSP19035377A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110248947B (zh) | 2022-04-01 |
| CL2019001335A1 (es) | 2019-10-04 |
| US9981930B1 (en) | 2018-05-29 |
| AU2017361250A1 (en) | 2019-05-30 |
| ES2908632T3 (es) | 2022-05-03 |
| JP2020502047A (ja) | 2020-01-23 |
| EP3541822A4 (en) | 2020-04-29 |
| AR110088A1 (es) | 2019-02-20 |
| MA46860A (fr) | 2019-09-25 |
| CA3043612A1 (en) | 2018-05-24 |
| EP3541822B1 (en) | 2022-01-19 |
| JP6987859B2 (ja) | 2022-01-05 |
| US20180134675A1 (en) | 2018-05-17 |
| ECSP19035377A (es) | 2019-05-31 |
| RU2019116514A (ru) | 2020-12-17 |
| PE20191146A1 (es) | 2019-09-02 |
| EA201991074A1 (ru) | 2019-12-30 |
| DOP2019000121A (es) | 2019-09-30 |
| TW201831458A (zh) | 2018-09-01 |
| KR20190077087A (ko) | 2019-07-02 |
| CR20190243A (es) | 2019-06-26 |
| CN110248947A (zh) | 2019-09-17 |
| TN2019000150A1 (en) | 2020-10-05 |
| MX2019005771A (es) | 2019-12-05 |
| JOP20190105A1 (ar) | 2019-05-09 |
| EP3541822A1 (en) | 2019-09-25 |
| BR112019009991A2 (pt) | 2019-08-27 |
| NI201900050A (es) | 2019-10-30 |
| IL266550A (en) | 2019-07-31 |
| PH12019501102A1 (en) | 2019-08-19 |
| WO2018093946A1 (en) | 2018-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019005059A2 (es) | Inhibidores de magl | |
| ECSP19035377A (es) | Inhibidores de magl | |
| NI202000080A (es) | Inhibidores de magl | |
| ECSP19083923A (es) | Inhibidores pirazólicos de magl | |
| CO2019004945A2 (es) | Inhibidores de la magl | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| ECSP19084085A (es) | Inhibidores pirazólicos de magl | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. |